Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Rethinking Molecular Profiling Post First-Line Osimertinib.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Improving neoadjuvant and perioperative therapy in non-small-cell lung cancer.

Nature reviews. Clinical oncology·2026
Same author

Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Deciphering small sequence differences in T cell receptor-antigen pairing.

Nature communications·2026
Same author

Sex Impacts Progression-Free Survival of Alectinib through Drug Exposure in Patients with <i>ALK-</i>Positive Non-Small Cell Lung Cancer.

Cancer communications (London, England)·2026
Same author

Clinical outcomes and predictors of response to PD-(L)1 blockade in patients with NSCLC without actionable genomic alterations who never used tobacco.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

相关实验视频

Updated: Jun 12, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.0K

非小细胞肺癌的非小细胞肺癌.

Lizza E L Hendriks1, Jordi Remon2, Corinne Faivre-Finn3

  • 1Department of Pulmonary Diseases, GROW-School for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, the Netherlands.

Nature reviews. Disease primers
|September 26, 2024
PubMed
概括

非小细胞肺癌 (NSCLC) 管理方面的进展,包括查,手术技术和向治疗,正在改善患者的治疗结果. 个性化治疗策略是NSCLC护理未来进展的关键.

更多相关视频

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.5K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K

相关实验视频

Last Updated: Jun 12, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.0K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.5K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K

科学领域:

  • 在瘤学瘤学.
  • 肺部病理学 肺部病理学
  • 癌症研究 癌症研究

背景情况:

  • 非小细胞肺癌 (NSCLC) 是全球癌症死亡的主要原因.
  • 在过去的十年中,最近的进展显著改善了NSCLC的治疗和患者的预后.
  • 改进的关键领域包括查,手术和放射治疗技术以及全身治疗.

研究的目的:

  • 审查非小细胞肺癌管理的近期改进.
  • 突出新策略对非转移性和转移性NSCLC患者结局的影响.
  • 强调个性化治疗概念的未来方向.

主要方法:

  • 审查最近的文献和NSCLC管理的临床进展.
  • 分析系统查 (低剂量CT) 对早期检测的影响.
  • 评估新的外科手术,放射治疗和全身治疗选择.

主要成果:

  • 通过外科手术期间的策略和局部晚期疾病的辅助免疫疗法,改善非转移性NSCLC的治愈率.
  • 通过新药的实施,在转移性NSCLC中长期控制疾病并保持生活质量.
  • 在了解NSCLC生物学方面取得了显著进展,这导致了创新的全身疗法.

结论:

  • 由于查,治疗方式和生物学理解的进步,NSCLC患者的预后得到了改善.
  • 组合策略和新型药物为早期和高级NSCLC提供了更好的结果.
  • 预测性临床和遗传标记的开发对于未来个性化NSCLC治疗至关重要.